Citius pharmaceuticals, inc. submits biologics license application to the u.s. food and drug administration for denileukin diftitox for the treatment of patients with persistent or recurrent cutaneous t-cell lymphoma

Cranford, n.j. , sept. 28, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the company has submitted a biologics license application (bla) to the u.s. food and drug administration (fda) for denileukin diftitox (i/ontak), an engineered il-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous t-cell lymphoma (ctcl).
CTXR Ratings Summary
CTXR Quant Ranking